Changes in Beneficial Ownership · 4
Neuropace, Inc.
NPCENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1795039777.xml
Filing details
- Report period
- 2026-11-18
- Issuer
- NeuroPace Inc
- Issuer CIK
- 0001528287
- Trading symbol
- NPCE
Reporting owner 1
- Name
- Huennekens R Scott
- Reporting owner CIK
- 0001365493
- Relationship
- Director
- Address
- C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership | Timeliness |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-18 | P · Form 5 | 12,500 | A[F1] | 8.2929[F2] | 12,500[F3] | I | By Front Foot Trust | E |
Table key
- P · Form 5
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- Purchases made in compliance with SEC Rule 10b-18 safe harbor restrictions for manner, timing, price, and volume of purchase. Purchases also complied with broker-dealer and issuer pre-clearance procedures.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.2350 to $8.3657, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.↩ 1
- F3
- Shares owned by the Front Foot Trust. Mr. Huennekens and a member of his immediate family serve as trustees of the trust. The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.↩ 1
Signature 1
- Signed
- /s/ Leah Akin, Attorney-in-Fact
- Date
- 2026-11-18
Company context
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.